Phase 1: Cmax: Single-Dose Maximum Observed Serum Concentration for Modakafusp Alfa [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: Tmax: Time to First Occurrence of Maximum Serum Concentration (Cmax) for Modakafusp Alfa [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Modakafusp Alfa [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: AUClast: Area Under the Serum Concentration-time Curve from Time 0 to Time of the Last Quantifiable Concentration [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: Apparent Serum Terminal Disposition Rate Constant for Modakafusp Alfa [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: Apparent Serum Terminal Disposition Phase Half-life for Modakafusp Alfa [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: Total Clearance After Intravenous Administration for Modakafusp Alfa [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: Volume of Distribution at Steady State After Intravenous Administration for Modakafusp Alfa [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: Cmax: Single-Dose Maximum Observed Serum Concentration for Daratumumab [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: Tmax: Time to First Occurrence of Maximum Serum Concentration (Cmax) for Daratumumab [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: Ctrough: Single-Dose and Multiple-dose Observed Concentration at the End of a Dosing Interval for Daratumumab [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: AUC∞: Area Under the Serum Concentration-time Curve from Time 0 to Infinity for Daratumumab [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: AUClast: Area Under the Serum Concentration-time Curve from Time 0 to Time of the Last Quantifiable Concentration for Daratumumab [Time Frame: Days 1, 8, 15, and 22 of Cycles 1 and 2: Pre-dose, and at multiple time points up to 4 hours post-dose; Day 2 of Cycles 1 and 2: Post-dose (cycle length=28 days)]
Phase 1: Overall Response Rate (ORR) [Time Frame: Up to 60 months]
Phase 1 and Phase 2a: Duration of Response (DOR) [Time Frame: Up to 60 months]
Phase 1 and Phase 2a: Progression Free Survival (PFS) [Time Frame: up to 60 months]
Phase 1 and Phase 2a: Overall Survival (OS) [Time Frame: Up to 60 months]
Phase 1 and Phase 2a: Number of Participants With Anti-drug Antibodies [Time Frame: Up to 60 months]
Phase 1 and Phase 2a: Titer of Anti-drug Antibodies [Time Frame: Up to 60 months]
Phase 1 and Phase 2a: Number of Participants With Neutralizing Antibodies (NAb) Against Study Drug [Time Frame: Up to 60 months]
Phase 1 and Phase 2a: Rate of Measurable [Minimal] Residual Disease Negative (MRD[-]) Complete Response (CR) [Time Frame: Up to 60 months]
Phase 1 and Phase 2a: Duration of Measurable [Minimal] Residual Disease (MRD) Negativity [Time Frame: Up to 60 months]
Phase 2a: Clinical Benefit Rate (CBR) [Time Frame: Up to 60 months]
Phase 2a: Duration of Clinical Benefit (DCB) [Time Frame: Up to 60 months]
Phase 2a: Disease Control Rate (DCR) [Time Frame: Up to 60 months]
Phase 2a: Duration of Disease Control [Time Frame: Up to 60 months]
Phase 2a: Time to Progression (TTP) [Time Frame: Up to 60 months]
Phase 2a: Time to Response (TTR) [Time Frame: Up to 60 months]
Phase 2a: Time to Next Treatment (TTNT) [Time Frame: Up to 60 months]
Phase 2a: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Per Severity [Time Frame: Up to 60 months]
